Jefferies & Co Upgrades Noven Pharmaceuticals (NOVN) to Hold
NOVN Hot Sheet
Rating Summary:0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 11 | New: 38
Jefferies & Co upgrades Noven Pharmaceuticals (Nasdaq: NOVN) from Underperform to Hold.
To see more analyst ratings on NOVN Click Here.
Noven Pharmaceuticals, Inc. (Noven) is a specialty pharmaceutical company engaged in the research, development, manufacturing, licensing, marketing and sale of prescription pharmaceutical products.
To see more analyst ratings on NOVN Click Here.
Noven Pharmaceuticals, Inc. (Noven) is a specialty pharmaceutical company engaged in the research, development, manufacturing, licensing, marketing and sale of prescription pharmaceutical products.
You May Also Be Interested In
- UPDATE: Auriga Upgrades Lifepoint Holdings (LPNT) to Buy; Use Recent Pullback As Opportunity
- Publicis Groupe Announces the Creation of saatchi&saatchi duke, a New Entity Combining the Saatchi & Saatchi and Duke Agencies in France
- GenVec Appoints Cynthia Collins as President and CEO
Create E-mail Alert Related Categories
UpgradesRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
